(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Soligenix Inc (NASDAQ:SNGX) shares rose 5.2% on Thursday after the company released positive findings from a Phase 2a ...

Please provide your email address to receive an email when new articles are posted on . The rare and complex Behcet’s disease is often misdiagnosed or undiagnosed, leading to significant, but ...

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

Soligenix has reported positive data from its Phase IIa trial of SGX945 (dusquetide) for the treatment of Behçet's disease. The proof-of-concept study examined SGX945 for treating oral ulcers in the ...

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...

Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.

Following these results, Soligenix plans to reformulate SGX945 to enable home-based treatment via subcutaneous injection. Behçet’s Disease affects up to 18,000 people in the U.S., 50,000 in Europe, ...

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Although BD may affect almost any system of the body with exacerbations and remissions of inflammation, the key clinical manifestations are recurrent oral aphthous ulcers, genital ulcers, uveitis and ...